ClinicalTrials.gg
CompletedNCT04080531Updated Feb 28, 2025Results posted

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders

A Phase 4 interventional study of Pneumococcal 13-valent Conjugate Vaccine and Trivalent Influenza Vaccine in Plasma Cell Neoplasm, sponsored by Emory University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Emory University · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 502 studies in Neoplasms, Plasma Cell with a site in United States — 26 open to participants now, 43 under way, 2 of them phase 3. Neoplasms, Plasma Cell · United States.

Enrollment
38th of 386
165 · median 33
Started
2019
with 8 others
Phase 4
4 of 502
1 open now
Registered
450th of 502
by date

Among the 502 studies in Neoplasms, Plasma Cell with a site in United States, this one is the 38th largest by enrollment of the 386 interventional ones that give a count, is one of 9 that started in 2019, is one of 4 in phase 4, and was the 450th registered.

Neoplasms, Plasma Cell

710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.

Browse Neoplasms, Plasma Cell studies →

Open to participants now

26 of the 502 studies in Neoplasms, Plasma Cell with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 502 studies in Neoplasms, Plasma Cell with a site in United States, or all of them as a file.
02

Study summary

This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders. Influenza infections may theoretically support the growth of tumor cells and improving protection against influenza may improve the status of patients' plasma cell disorder. Giving influenza vaccination may reduce influenza-related complications including infections, hospitalizations, and deaths, and improve the status of plasma cell disorders.

Read the detailed description

PRIMARY OBJECTIVES:

I. Demonstrate an absolute 25% increase in seroprotection, defined as hemagglutination antibody inhibition (HAI) > 40 against all strains, at week 21 in the experimental arm compared to the control arm.

II. Determine correlation between HAI, predefined risk of influenza-like illness (low, moderate, high), and progression-free survival (PFS).

EXPLORATORY OBJECTIVES:

I. Measurement of B \& T-cell subsets and flu-specific responses as a way of understanding immunosuppression in this patient population, correlating with influenza-like illness.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive trivalent influenza vaccine intramuscularly (IM) at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for 4 weeks and then periodically for 2 years.

03

Conditions studied

  • Plasma Cell Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must have a plasma cell dyscrasia that fits in the International Myeloma Working Group (IMWG) diagnostic criteria.
  • Both men and women of all races and ethnic groups are eligible for this study.
  • (ECOG) performance status ≤ 3 ( ≥ 30%) is required for eligibility.
  • Patient must be eligible to receive standard of care influenza vaccination. If the patient has a history of egg allergy with symptoms more severe than urticaria, e.g. angioedema, respiratory distress, lightheadedness, or recurrent emesis, they remain eligible to receive influenza vaccination but must receive the vaccine in a facility able to recognize and manage severe allergic reactions. Persons who are able to eat lightly cooked egg (e.g., scrambled egg) without reaction are unlikely to be allergic, although egg-allergic persons might tolerate egg in baked products.
  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Patients who have already received the seasonal influenza vaccine in the current season.
  • History of Guillain-Barré syndrome.
  • Patients with a previous severe allergic reaction to influenza vaccination or pneumococcal 13-valent conjugate vaccine (PCV13).
  • Expected survival \< 9 months.
  • Prisoners.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (actual)

Study arms

  • Experimental
    Arm I (trivalent influenza vaccine, Prevnar)

    Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.

    Biological: Pneumococcal 13-valent Conjugate Vaccine · Biological: Trivalent Influenza Vaccine

  • Experimental
    Arm II (trivalent influenza vaccine, Prevnar)

    Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity.

    Biological: Pneumococcal 13-valent Conjugate Vaccine · Biological: Trivalent Influenza Vaccine

Interventions

  • Given IM

    Also known as: PCV13, Prevnar 13

  • BiologicalTrivalent Influenza Vaccine

    Given IM

    Also known as: Flu shot, Flu vaccination, Fluzone, Fluzone HD, Fluzone High-dose, Influenza Vaccine, Influenza Virus Vaccine, Trivalent, Types A and B, TIV

06

What researchers measure

Primary outcomes

  1. Seroprotection Based on Hemagglutination Antibody Inhibition (HAI)

    HAI in blood at week 21 for all variants

    Time frame: 21 weeks

07

Results

Posted Feb 28, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm I (Trivalent Influenza Vaccine, Prevnar)Arm II (Trivalent Influenza Vaccine, Prevnar)
Started8085
Completed6481
Not completed164

Outcome measures

PrimarySeroprotection Based on Hemagglutination Antibody Inhibition (HAI)

HAI in blood at week 21 for all variants

Time frame:
21 weeks
Reported as:
Count of participants · Participants
Seroprotection Based on Hemagglutination Antibody Inhibition (HAI)
ParticipantsArm I (Trivalent Influenza Vaccine, Prevnar)Arm II (Trivalent Influenza Vaccine, Prevnar)
Seroprotection Based on Hemagglutination Antibody Inhibition (HAI)3222

Adverse events

Collected over 1 year. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm I (Trivalent Influenza Vaccine, Prevnar)3/80 (3.8%)0/80 (0%)0/80 (0%)
Arm II (Trivalent Influenza Vaccine, Prevnar)1/85 (1.2%)0/85 (0%)0/85 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm I (Trivalent Influenza Vaccine, Prevnar)Arm II (Trivalent Influenza Vaccine, Prevnar)Total
<=18 years000
Between 18 and 65 years464793
>=65 years343872
Age, Continuous
Age, Continuous(years)Arm I (Trivalent Influenza Vaccine, Prevnar)Arm II (Trivalent Influenza Vaccine, Prevnar)Total
Mean61.7 ± 11.6062.8 ± 9.6862.35 ± 10.63
Sex: Female, Male
Sex: Female, Male(Participants)Arm I (Trivalent Influenza Vaccine, Prevnar)Arm II (Trivalent Influenza Vaccine, Prevnar)Total
Female373067
Male435598
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm I (Trivalent Influenza Vaccine, Prevnar)Arm II (Trivalent Influenza Vaccine, Prevnar)Total
Hispanic or Latino213
Not Hispanic or Latino7083153
Unknown or Not Reported819
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm I (Trivalent Influenza Vaccine, Prevnar)Arm II (Trivalent Influenza Vaccine, Prevnar)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander101
Black or African American222749
White5154105
More than one race000
Unknown or Not Reported549
Region of Enrollment
Region of Enrollment(participants)Arm I (Trivalent Influenza Vaccine, Prevnar)Arm II (Trivalent Influenza Vaccine, Prevnar)Total
United States8085165
08

Study locations

2 sites
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
  • Emory University Hospital/Winship Cancer Institute
    Atlanta, Georgia 30322, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in May 2021, 18 months.

Results were first posted in Feb 2025, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2019
First posted
Sep 6, 2019
StartActual
Oct 18, 2019
Primary completionActual
May 11, 2021
CompletionActual
Dec 15, 2022
Results first posted
Feb 28, 2025
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04080531
Lead sponsor
Emory University
Responsible party
Craig Hofmeister (Principal Investigator, Emory University) — Principal investigator
First posted
Sep 6, 2019
Start date
Oct 18, 2019
Primary completion
May 11, 2021
Completion
Dec 15, 2022
Results posted
Feb 28, 2025
Last update
Feb 28, 2025

Study contacts

Craig Hofmeister, MD, MPH
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion